ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics CEO Aslan Fred’s recent sell‑to‑cover of 23,463 shares at $7.20 shows routine, tax‑cover activity with minimal impact on the stock’s value. This disciplined insider selling keeps long‑term ownership stable while providing inve…

Artiva Biotherapeutics CEO Aslan Fred buys 425k shares—boosting confidence in its immunotherapy pipeline and potential reimbursement upside.

Artiva Biotherapeutics insider buys signal strong confidence: CEO’s share purchase, expanded incentive plan, and early‑stage AlloNK & CAR‑NK trials show low side‑effects and promising response rates, hinting at 2028 approval and upside.

RA Capital’s steady build at Artiva Biotherapeutics signals confidence in its NK‑cell platform—watch the 2027 option grant for potential dilution and market shifts.

Artiva Biotherapeutics’ insider buying signals confidence in its NK‑cell platform and upcoming trials, highlighting a strategic move to boost talent retention and investor sentiment.

Artiva Biotherapeutics insider buys reveal confidence in its late‑stage oncology pipeline, highlighting a strategic focus on high‑value, first‑in‑class cancer therapies and potential market upside.

Artiva insider trading: CMO Subhashis Banerjee’s 10b5‑1 buys and sells show steady confidence in the biotech’s growth, hinting at future upside for investors.